12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Company News  |  Other News

Amarin cardiovascular news

Amarin filed a response with the U.S. Patent and Trademark Office (PTO) to a November non-final rejection letter for a patent application covering the company's lead candidate, AMR101. The letter rejected some claims as being unpatentable for obviousness, which Amarin seeks to address in the amended application. Amarin amended the scope of use to "lowering triglycerides and

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >